Giralt M, Rubio D, Cortés M T, San Miguel J, Steegmann J L, Serena J, Fernández-Rañada J M, López-Borrasca A
Department of Hematology, Hospital Miguel Servet, Zaragoza, Spain.
Eur J Cancer. 1991;27 Suppl 4:S72-4. doi: 10.1016/0277-5379(91)90579-3.
Thirteen patients (mean age 60.7 years; female:male ratio 10:3) with essential thrombocythaemia were treated with 3 million units (MU)/day interferon alfa-2b subcutaneously (s.c.) for 12 weeks, with all patients requiring a dose reduction after 4 weeks. The mean pretreatment platelet count was 1,400 x 10(9)/L and megakaryocytes were increased in all cases. Splenomegaly was present in six patients and haemorrhagic phenomena were observed in two. Nine patients (69.2%) had objective responses, including two (15.4%) complete responses (platelets less than 450 x 10(9)/L) which were then maintained with 5 MU interferon twice a week. Acute toxicity consisted of flu-like symptoms in 12 patients. Chronic toxicity (mainly leucopenia) was observed in nine patients. In conclusion, initial therapy and then requiring maintenance therapy at a reduced dose. However, the frequent side effects observed make it advisable to use a low dose of interferon alfa-2b, and to treat only those patients with significant symptoms and signs of thrombocytosis.
13例原发性血小板增多症患者（平均年龄60.7岁；男女比例为10:3）接受皮下注射300万单位（MU）/天的干扰素α-2b治疗，疗程12周，所有患者在4周后均需减量。治疗前血小板计数平均为1400×10⁹/L，所有病例巨核细胞均增多。6例患者有脾肿大，2例观察到出血现象。9例患者（69.2%）有客观反应，其中2例（15.4%）完全缓解（血小板低于450×10⁹/L），随后以5MU干扰素每周两次维持治疗。急性毒性表现为12例患者出现流感样症状。9例患者观察到慢性毒性（主要为白细胞减少）。总之，初始治疗后需要减量维持治疗。然而，观察到的频繁副作用表明，宜使用低剂量的干扰素α-2b，且仅治疗那些有明显血小板增多症状和体征的患者。
